164 related articles for article (PubMed ID: 24625356)
1. Investigational inhibitors of PTP4A3 phosphatase as antineoplastic agents.
Sharlow ER; Wipf P; McQueeney KE; Bakan A; Lazo JS
Expert Opin Investig Drugs; 2014 May; 23(5):661-73. PubMed ID: 24625356
[TBL] [Abstract][Full Text] [Related]
2. Next-Generation Cell-Active Inhibitors of the Undrugged Oncogenic PTP4A3 Phosphatase.
Lazo JS; Blanco IK; Tasker NR; Rastelli EJ; Burnett JC; Garrott SR; Hart DJ; McCloud RL; Hsu KL; Wipf P; Sharlow ER
J Pharmacol Exp Ther; 2019 Dec; 371(3):652-662. PubMed ID: 31601683
[TBL] [Abstract][Full Text] [Related]
3. Phosphatases as targets for cancer treatment.
Lazo JS; Wipf P
Curr Opin Investig Drugs; 2009 Dec; 10(12):1297-304. PubMed ID: 19943201
[TBL] [Abstract][Full Text] [Related]
4. Protein tyrosine phosphatases in cancer: friends and foes!
Labbé DP; Hardy S; Tremblay ML
Prog Mol Biol Transl Sci; 2012; 106():253-306. PubMed ID: 22340721
[TBL] [Abstract][Full Text] [Related]
5. A chemical genetics approach identifies PTP4A3 as a regulator of colon cancer cell adhesion.
McQueeney KE; Salamoun JM; Ahn JG; Pekic P; Blanco IK; Struckman HL; Sharlow ER; Wipf P; Lazo JS
FASEB J; 2018 Oct; 32(10):5661-5673. PubMed ID: 29746167
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of bifunctional PTP4A3 phosphatase inhibitors activating the ER stress pathway.
Rastelli EJ; Sannino S; Hart DJ; Sharlow ER; Lazo JS; Brodsky JL; Wipf P
Bioorg Med Chem Lett; 2021 Aug; 46():128167. PubMed ID: 34089839
[TBL] [Abstract][Full Text] [Related]
7. Role of tyrosine phosphatase inhibitors in cancer treatment with emphasis on SH2 domain-containing tyrosine phosphatases (SHPs).
Irandoust M; van den Berg TK; Kaspers GJ; Cloos J
Anticancer Agents Med Chem; 2009 Feb; 9(2):212-20. PubMed ID: 19199865
[TBL] [Abstract][Full Text] [Related]
8. New phosphatidylinositol 3-kinase inhibitors for cancer.
Bowles DW; Jimeno A
Expert Opin Investig Drugs; 2011 Apr; 20(4):507-18. PubMed ID: 21395485
[TBL] [Abstract][Full Text] [Related]
9. Molecular targets in the discovery and development of novel antimetastatic agents: current progress and future prospects.
Wong MS; Sidik SM; Mahmud R; Stanslas J
Clin Exp Pharmacol Physiol; 2013 May; 40(5):307-19. PubMed ID: 23534409
[TBL] [Abstract][Full Text] [Related]
10. Proprotein convertase inhibition: Paralyzing the cell's master switches.
Klein-Szanto AJ; Bassi DE
Biochem Pharmacol; 2017 Sep; 140():8-15. PubMed ID: 28456517
[TBL] [Abstract][Full Text] [Related]
11. Protein tyrosine phosphatases as drug targets: strategies and challenges of inhibitor development.
Barr AJ
Future Med Chem; 2010 Oct; 2(10):1563-76. PubMed ID: 21426149
[TBL] [Abstract][Full Text] [Related]
12. Targeting PRL phosphatases in hematological malignancies.
Xiao S; Chen H; Bai Y; Zhang ZY; Liu Y
Expert Opin Ther Targets; 2024 Apr; 28(4):259-271. PubMed ID: 38653737
[TBL] [Abstract][Full Text] [Related]
13. Rhodanine-based PRL-3 inhibitors blocked the migration and invasion of metastatic cancer cells.
Min G; Lee SK; Kim HN; Han YM; Lee RH; Jeong DG; Han DC; Kwon BM
Bioorg Med Chem Lett; 2013 Jul; 23(13):3769-74. PubMed ID: 23726031
[TBL] [Abstract][Full Text] [Related]
14. Dual-specificity phosphatases as targets for antineoplastic agents.
Lyon MA; Ducruet AP; Wipf P; Lazo JS
Nat Rev Drug Discov; 2002 Dec; 1(12):961-76. PubMed ID: 12461518
[TBL] [Abstract][Full Text] [Related]
15. Effect of protein-tyrosine phosphatase 4A3 by small interfering RNA on the proliferation of lung cancer.
Lian YX; Chen R; Xu YH; Peng CL; Hu HC
Gene; 2012 Dec; 511(2):169-76. PubMed ID: 23036709
[TBL] [Abstract][Full Text] [Related]
16. In-flow photooxygenation of aminothienopyridinones generates iminopyridinedione PTP4A3 phosphatase inhibitors.
Tasker NR; Rastelli EJ; Blanco IK; Burnett JC; Sharlow ER; Lazo JS; Wipf P
Org Biomol Chem; 2019 Feb; 17(9):2448-2466. PubMed ID: 30746541
[TBL] [Abstract][Full Text] [Related]
17. Credentialing and Pharmacologically Targeting PTP4A3 Phosphatase as a Molecular Target for Ovarian Cancer.
Lazo JS; Sharlow ER; Cornelison R; Hart DJ; Llaneza DC; Mendelson AJ; Rastelli EJ; Tasker NR; Landen CN; Wipf P
Biomolecules; 2021 Jun; 11(7):. PubMed ID: 34209460
[TBL] [Abstract][Full Text] [Related]
18. Structure of the Complex of an Iminopyridinedione Protein Tyrosine Phosphatase 4A3 Phosphatase Inhibitor with Human Serum Albumin.
Czub MP; Boulton AM; Rastelli EJ; Tasker NR; Maskrey TS; Blanco IK; McQueeney KE; Bushweller JH; Minor W; Wipf P; Sharlow ER; Lazo JS
Mol Pharmacol; 2020 Dec; 98(6):648-657. PubMed ID: 32978326
[TBL] [Abstract][Full Text] [Related]
19. Investigational platelet-derived growth factor receptor kinase inhibitors in breast cancer therapy.
Criscitiello C; Gelao L; Viale G; Esposito A; Curigliano G
Expert Opin Investig Drugs; 2014 May; 23(5):599-610. PubMed ID: 24597540
[TBL] [Abstract][Full Text] [Related]
20. Molecular Targets of Active Anticancer Compounds Derived from Marine Sources.
Song X; Xiong Y; Qi X; Tang W; Dai J; Gu Q; Li J
Mar Drugs; 2018 May; 16(5):. PubMed ID: 29786660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
